Cabot Announces Inauguration of its Fumed Silica Manufacturing Plant
By Akshay Kedari  Date: 2019-09-25

Cabot Announces Inauguration of its Fumed Silica Manufacturing Plant

With increasing urban population in China, there is an noticeable increase in demand for automotive, construction, and infrastructural developments. Fumed silica is used in these sectors because of its enhanced performance capabilities, versatility, and durability. Industry leaders in China are also putting in their best to meet the demands for fumed silica by enhancing production capacity.

A similar instance occurred recently when, Cabot Corporation, a global specialty chemicals and performance materials company, reportedly announced the grand opening of its fumed silica manufacturing facility in Wuhai, China.

Sources cite that this newest manufacturing site will add approx. 8,000 metric tons of yearly fumed silica capacity to the global network of Cabot, and will fulfill the rapidly growing demand of fumed silica in China. Moreover, with this facility, Cabot will become the leading fumed silica provider in the country.

Announced in Sept. 2016, the project is a joint venture between Cabot and Inner Mongolia Hengyecheng Silicone, also referred as HYC.

According to reports, Cabot has around 80% equity interest in the facility and brings in advanced technology for fumed silica production, and is one the leading companies in China. Whereas HYC is claimed to be operating with Cabot to maximize byproduct streams and eliminate waste.

Sean Keohane, Chief Executive Officer and President, Cabot Corporation, claims that the grand opening of a silica manufacturing facility is a vital milestone in executing the company’s ‘Advancing the Core’ strategy.

Whereas Jay Doubman, Senior Vice President and President, Performance Additives, Cabot Corporation, claims that silica manufacturing capabilities will help their company reach customers in the part of China where it expects a significant development and growth in the coming year.

Doubman later said that the company will be innovating new solutions in fumed silicas by blending Wuhai manufacturing facility and technical expertise at the firm’s Asia Technology Center in Shanghai for a more sustainable future.

Source Credit - http://investor.cabot-corp.com/node/20421

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...